← Back to Clinical Trials
Recruiting Phase 2 NCT07102550

NCT07102550 Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07102550
Status Recruiting
Phase Phase 2
Sponsor Choon Hyuck David Kwon
Condition Liver Transplant
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-10-29
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
MiMedx AmnioFix

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 40 participants in total. It began in 2024-10-29 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this single armed, non-randomized, pilot study is to demonstrate that placental tissue grafts are safe in living donor liver transplant and assess their impact on biliary outcomes in adults.

Eligibility Criteria

Inclusion Criteria: * Adults \>/= 18 years old * Recipient of LDLT Exclusion Criteria: * Patients who are deemed unsafe for participation for any reason by our multi-disciplinary liver transplant selection committee. * Patients \< 18 years old * Patients who cannot provide informed consent * Patients receiving deceased donor liver transplants, or who are not undergoing Liver transplant (LT) * Patients who do not wish to participate * Children, cognitively-impaired persons, pregnant women, students and house staff under the direct supervision of the investigator are considered vulnerable populations and will, therefore, be excluded from participation.

Contact & Investigator

Central Contact

Erlind Allkushi

✉ allkuse2@ccf.org

📞 2164440223

Principal Investigator

Choon Hyuck D Kwon, MD, PhD

PRINCIPAL INVESTIGATOR

The Cleveland Clinic

Frequently Asked Questions

Who can join the NCT07102550 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07102550 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07102550 currently recruiting?

Yes, NCT07102550 is actively recruiting participants. Contact the research team at allkuse2@ccf.org for enrollment information.

Where is the NCT07102550 trial being conducted?

This trial is being conducted at Cleveland, United States.

Who is sponsoring the NCT07102550 clinical trial?

NCT07102550 is sponsored by Choon Hyuck David Kwon. The principal investigator is Choon Hyuck D Kwon, MD, PhD at The Cleveland Clinic. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology